The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria ...
GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and ...